Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 and Figure S6 from Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target
Year: 2023
Type: other
Abstract: Figure S1. DTCs upregulate TORC1-mediated MCL-1 translation. Figure S2. High-content cell imaging assay. Figure S3. Genetic inhibition of MCL-1 is sufficient to induce apoptosis following EGFR inhibitor treatment. Figure S4. EGFR mutant tumors (PC9) respond to EGFR inhibitor/MCL-1 inhibitor (S63845) combination therapy in vivo. Figure S5. EGFR mutant tumors (HCC827) respond to EGFR inhibitor/MCL-1 inhibitor (S63845) combination therapy in vivo. Figure S6. Upregulation of MCL-1 in EGFR mutant cell lines occurs with other insults.
Authors: Kyung-A Song, Yasuyuki Hosono, Crystal Turner, Sheeba Jacob, Timothy L. Lochmann, Yoshiko Murakami, Neha U. Patel, Jungoh Ham, Bin Hu, Krista M. Powell, Colin M. Coon, Brad E. Windle, Yuko Oya, Jennifer E. Koblinski, Hisashi Harada, Joel D. Leverson, Andrew J. Souers, Aaron N. Hata, Sosipatros Boikos, Yasushi Yatabe, Hiromichi Ebi, Anthony C. Faber
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362406534